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Abstract
Background: Oral Candida colonization and its relation with predisposing factors in HIV-infected patients have
received wide concerns during recent decades. In this study, we investigated asymptomatic oral Candida carriage
rate, species distribution and antifungal susceptibility of 604 HIV-infected patients and 851 healthy individuals in
Kunming, Yunnan Province of China.
Methods: Mucosal swab sampling was taken from each subject and CHROMagar Candida agar medium and
API 20C AUX system were used to identify yeast isolates. In vitro antifungal susceptibility was tested by the
broth microdilution method according to the M27-A2 document of the Clinical and Laboratory Standard
Institute (CLSI).
Results: The oral yeast colonization rate in HIV-infected patients (49.5%) was higher than that of healthy
subjects (20.7%). Candida albicans constituted the most frequent species, accounting for 82.2% of yeast
isolates. The remaining species were composed of C. glabrata, C. parapsilosis, C. krusei, C. tropicalis, C. rugosa,
C. norvegensis, Pichia ohmeri and Saccharomyces cerevisiae. In HIV-infected patients, asymptomatic oral yeast
colonization was associated with low CD4 cell count (<200 cells/mm3) and lack of highly active antiretroviral
therapy (HAART). Different Candida species isolated from our samples presented different susceptibility to
voriconazole, fluconazole and itraconazole. Amphotericin B had the best inhibiting effect for all isolates.
Conclusion: Oral yeast colonization in Han Chinese patients with HIV from Kunming had common and
unique features and was associated with CD4 cell number and HARRT. Amphotericin B should be used with
first priority in controlling Candida infection in Han Chinese patients from Kunming. Our results provide first
hand information on monitoring oral yeasts colonization in HIV-infected patients from Kunming, China.
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Background
It is estimated by the Chinese Ministry of Health and
the Joint United Nations Programme on HIV/AIDS
(UNAIDS) that at the end of 2009, there were 740,000
living people infected with human immunodeficiency
virus (HIV) in China, including 105,000 patients
suffering acquired immunodeficiency syndrome (AIDS)
[1]. Among these HIV/AIDS endemic areas, Yunnan
Province is heavily affected and has the longest history
of infection in China, simply because of diverse ethnic
composition and bordering with the “Golden triangle” of
illicit opium production [2]. Despite of remarkable evolu-
tion of China’s response to HIV/AIDS [3] and achieve-
ments regarding the coverage on highly active antiretroviral
therapy (HARRT) and the decrease of HIV-related mortal-
ity, urgent needs are required for early HIV diagnosis, bet-
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Candida species are composed of commensal fungal
organisms and opportunistic pathogens of mucosal tissues
[5]. These species can lead to a variety of mucosal infections
under the imbalance of oral microflora or suffering
with systemic diseases. Human resistance to Candida
was affected by innate and acquired immunity [5]. In
HIV-infected patients, there are many reports for a high
incidence of asymptomatic oral yeast carriage [6-11]. In
particular, oropharyngeal candidiasis (OPC) is the most
frequent opportunistic infection, with a occurrence rate in
50% to 90% of patients during disease progression [12].
Presence of asymptomatic carriage of yeasts in the oral
cavities of HIV-infected patients and lower CD4 cell count
have been associated with subsequent development of
OPC [6,13]. Among Candida species isolated from the
oral cavity, Candida albicans is the most prevalent spe-
cies; there are many other yeast species characterized by
low susceptibility to azole, such as C. glabrata, C. krusei,
C. tropicalis, C. parapsilosis [14,15]. Previous study have
shown that HAART decreased the incidence of all HIV-
related opportunistic infections including fungal infec-
tion [16], but there are conflicting reports regarding the
association between oral yeast colonization and HAART
[6,7,17-19]. Monitoring the antifungal susceptibility of
clinical isolates from patients with HIV/AIDS has crucial
importance for better treatment of these patients [20].
Hitherto, large-scale investigations have not been suffi-
ciently performed to characterize the oral fungal carriage
rate, species prevalence and antifungal susceptibility
among HIV-infected individuals in China. In this study,
we analyzed 604 HIV-infected patients and 851 healthy
individuals in Kunming, Yunnan Province, China, with an
intention to (1) determine the carriage rate and species
distribution in HIV-infected patients and healthy indivi-
duals from Kunming, (2) to investigate the risk factors
associated with oral yeast colonization among HIV-
infected patients, and (3) to evaluate antifungal suscepti-




HIV-infected patients from Yunnan Provincial Hospital of
Infectious Disease/AIDS Care Center (YNACC) were
recruited in this study from June 2009 to November 2009.
Patients were eligible for the study if they received no
treatment with antifungal or antimicrobial agents during
the previous 6 months before sampling and had no sign
for clinical evidence of OPC according to the criteria of
the EC-Clearinghouse on oral problems related to HIV in-
fection [21]. A total of 604 patients from Kunming met
the criteria and were analyzed in this study. Clinical and
demographic data taken at the time of oral examination
for each patient included the following items: age, gender,
marriage, mode of HIV transmission, CD4 cell count, and
HAART. Simply for convenience and for comparison with
the HIV-infected patients, we randomly collected 851
healthy donors from Kunming who attended routine
physical examinations at the First Affiliated Hospital of
Kunming Medical University and were confirmed to be
HIV-negative and without any clinical sign for OPC.
Informed consents conforming to the tenets of the Declar-
ation of Helsinki were obtained from each participant
prior to this study. The institutional review board of the
First Affiliated Hospital of Kunming Medical University
approved this study.
Sample collection and culture
Samples were obtained by swabbing buccal mucosa and
tongue with a sterile cotton swab, then were plated onto
Sabouraud’s dextrose agar (SDA) (bioMérieux, France)
and incubated at 37°C for 48 h. Yeast colonies growing on
each SDA tube were resuspended and 10 μL of suspension
solution was used to inoculate plates with CHROMagar
Candida agar medium (CHROMagar Company, France),
followed by a two-day culture at 37°C [22]. We tentatively
classified yeast species according to the colour of each col-
ony: green colonies were identified as C. albicans or C.
dubliniensis; dark green colonies were grouped as C.
dubliniensis; colonies with blue, pink and mauve colours
were regarded as C. tropicalis, C. krusei and C. glabrata
[23]. Isolates of C. albicans were further studied by the
germ-tube test and chlamydospore production. Colonies
of non-C. albicans species were subcultured on new SDA
medium, and species identifications were validated by API
20C AUX system for yeasts (bioMérieux, France). Dis-
crimination between C. albicans and C. dubliniensis was
investigated by analyses of germ tube formation in calf
serum at 37°C for 3 h, degree of chlamydospore produc-
tion on cornmeal agar supplemented with 1% tween-80
growth at 45°C on SDA, colony morphology at Staib agar,
and xylose assimilation test.
Antifungal susceptibility testing
In vitro antifungal susceptibility was tested by the broth
microdilution method according to the M 27-A2 docu-
ment of the Clinical and Laboratory Standard Institute
(CLSI) [24]. Four antifungal agents (amphotericin B,
itraconazole, fluconazole and voriconazole) obtained
from Sigma (USA) were used. These four drugs were
widely used in our clinical center to cure patients with
fungal infection. The culture medium was RPMI-1640
with L-glutamine but no bicarbonate, and buffered at
pH 7.0 with 0.165 mol/L MOPS. The range of drug con-
centration was 0.125-64 μg/mL for fluconazole and
0.031-16 μg/mL for all three drugs (amphotericin B, itra-
conazole and voriconazole). Cell density of inoculum
suspension was adjusted with a spectrophotometer and
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was diluted to achieve a final concentration of 1 × 103 to
5 × 103 cells / mL by RPMI-1640. The microplates were
incubated at 35°C and end point read at 48 h. The min-
imal inhibitory concentration (MIC) of amphotericin B
was defined as the lowest concentration that prevents
any discernible growth. The MIC for azole was defined
as the lowest concentration that sharply decreases the
growth relative to the control, as it is not possible to dis-
tinguish the difference between 50% and 80% inhibition
by eye when using the microdilution method. Suscep-
tible (S) breakpoints were set as MIC ≤8 μg/mL for flu-
conazole, ≤0.125 μg/mL for itraconazole, <1 μg/mL for
voriconazole and ≤ 1 μg/mL for amphotericin B, respect-
ively. Species with MICs between 16 μg/mL and 32 μg/mL
for fluconazole and between 0.25 μg/mL and 0.5 μg/mL
for itraconazole were considered as susceptible–dose
dependent (S-DD). Species with MICs ≥64 μg/mL for
fluconazole, ≥1 μg/mL for itraconazole and voriconazole,
and >1 μg/mL for amphotericin B were considered as re-
sistant (R) [8,24]. Quality control was performed by testing
the reference strains of C. parapsilosis ATCC 22019 and
C. krusei ATCC 6258.
Data analysis
Statistical analysis was performed by SPSS Version 16.0.
Differences of gender, marriage, mode of HIV transmis-
sion and HAART were assessed by the Chi-squared test
between the HIV infected patients with and without oral
yeast colonization. Differences of age and CD4 cell count
were evaluated by the Mann–Whitney test as these vari-
ables were non-normally distributed in our patients. We
also conducted binary logistic regression analysis to
determine whether differences in cases and controls re-
main after adjustment for socio-demographic and clinical
characteristics. A P value of <0.05 was considered as sta-
tistically significant.
Results
The patients with HIV (230 female and 374 male) had a
median age of 37.7 years old (range from 18 to 75 years
old). Among these patients, around 45.2% (273/604) was
infected through heterosexual contact, while 26.5% of them
(160/604) was injecting drug user (IDU), followed by
homosexual male (22/604 = 3.6%). Only five patients (0.8%)
were affected via transfusion and one patient (0.2%) was a
blood and plasma donor. The remaining 143 patients
(23.7%) had self-reported an unclear history of HIV infec-
tion. The average CD4 cell count was 253.4 cells/mm3,
with a range from 2 to 1050 cells/mm3 in all patients. Most
of patients (502/604 = 83.1%) were treated with HAART.
Of the treated subjects, antiretroviral regimen of 481
patients (95.8%) was 2 NRTIs (nucleoside reverse tran-
scriptase inhibitors) + 1 NNRTI (non-nucleoside reverse
transcriptase inhibitor). Only 21 patients (4.2%) received
2NRTIs + 1PI (protease inhibitor). The control group con-
sisted of 411 male and 440 female healthy donors, with a
mean age of 39.3 years old (range from 18 to 74 years old).
Oral yeast carriage rates were 49.5% (299/604) in HIV-
infected patients and 20.7% (176/851) in healthy controls,
and the difference was statistically significant (Chi-square
test, P < 0.001). The distribution of fungal species among
oral isolates collected from HIV-infected subjects and con-
trols were shown in Table 1. In HIV-infected patients, C.
albicans accounted for 82.2% of the recognized species. We
Table 1 Distribution of oral yeast isolates in 604 HIV-infected patients and 851 healthy subjects from Kunming,
Yunnan Province of China
Species HIV-infected patients Healthy subjects a
Occurrence of
species (%) a




Proportion of HIV-infected patients
with colonization b
C. albicans 263 (82.2) 43.5 131 (73.2) 15.4
C. glabrata 29 (9.1) 4.8 17 (9.5) 2.0
C. parapsilosis 12 (3.8) 2.0 21 (11.7) 2.5
C. krusei 10 (3.1) 1.7 3 (1.7) 0.4
C. tropicalis 2 (0.6) 0.3 4 (2.2) 0.5
C. rugosa 1 (0.3) 0.2 0 (0.0) 0.0
C. norvegensis 1 (0.3) 0.2 0 (0.0) 0.0
C. lusitaniae 0 (0.0) 0.0 1 (0.6) 0.1
C. guilliermondii 0 (0.0) 0.0 1 (0.6) 0.1
Pichia ohmeri 1 (0.3) 0.2 1 (0.6) 0.1
Saccharomyces cerevisiae 1 (0.3) 0.2 0 (0.0) 0.0
Total 320 (100.0) − 179 (100.0) −
a The values in parentheses refer to frequency of each species in all oral yeast isolates.
b Multiple species isolation was counted according to the presence of each species in a donor.
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also identified C. glabrata, C. parapsilosis, C. krusei, C. tro-
picalis, C. rugosa, C. norvegensis, Pichia ohmeri and Sac-
charomyces cerevisiae, albeit at different frequencies. C.
albicans was also the prevalent isolated species (73.2%) in
the control group, but the frequency was significantly lower
than that of HIV-infected patients (P = 0.022). We identified
C. lusitaniae in one healthy donor and C. guilliermondii in
another healthy donor but not in any HIV-infected patients
(Table 1). There are several cases with multiple species iso-
lation among oral isolates collected from both the patients
(21/299) and controls (3/176), despite the fact that this is
more common in patients with HIV (Additional file 1).
We performed association analysis to discern predis-
posing factors for oral fungal colonization. There are sig-
nificant differences in CD4 cell count (Mann-Whithney
test, P = 0.019) and HAART (Chi-square test, P = 0.00002)
between patients with and without oral fungal colonization.
However, carriage of oral yeast was not associated
with mean age (Mann-Whithney test, P = 0.837), gen-
der (Chi-square test, P = 0.981), marriage (Chi-square
test, P = 0.703), and HIV transmission (Chi-square test,
P = 0.351). There was no difference regarding the fre-
quency of oral yeast colonization between the two
group of patients treated with different antiretroviral
regimens (Chi-square test, P = 0.851) (Table 2). Similar
results were obtained when we conducted the adjusted
analysis using the binary logistic regression modeling
to determine whether differences in cases and controls
remain after adjustment for socio-demographic and
clinical characteristics (Additional file 2).
The MIC range, number of S strains, number of S-DD
strains, and number of R strains to fluconazole, itracona-
zole, voriconazole and amphotericin B for oral yeast
isolates from HIV-infected patients and healthy subjects
were listed in Tables 3 and 4, respectively. Eighteen iso-
lates (5.6%) were resistant to fluconazole, 44 (13.8%)
were resistant to itraconazole, and 17 (5.3%) were re-
sistant to voriconazole. All of the isolates were suscep-
tible to amphotericin B (Table 3). Among those healthy
subjects, 5 (2.8%) were resistant to fluconazole, 23
(12.8%) were resistant to itraconazole, and 4 (2.2%)
were resistant to voriconazole. None of the isolates
from healthy donors were resistant to amphotericin B
(Table 4).
Discussion
Oral yeast colonization in Han Chinese patients with HIV
from Kunming had common and unique features
In this study, we screened oral fungal colonization in the
largest cohort of Han Chinese patients with HIV from
Table 2 Association of oral yeast colonization with demographic and clinical features in 604 HIV-infected patients from
Kunming, Yunnan Province of China
Parameter Colonized Non-colonized P-value
n = 299 (%) n = 305 (%)
Mean age (years) 38.0 ± 10.8 37.5 ± 9.2 0.837 a
Gender (female) 114 (38.1) 116 (38.0) 0.981b
Marriage Unmarried 79 (26.4) 79 (25.9) 0.703
Married 202 (67.6) 200 (65.6)
Divorced 14 (4.7) 20 (6.6)
Widowhood 4 (1.3) 6 (2.0)
Transmission Injecting drug user 83 (27.8) 77 (25.2) 0.605
Heterosexual sex 131 (43.8) 142 (46.6)
Homo/bisexual male 8 (2.7) 14 (4.6)
Transfusion recipient 3 (1.0) 2 (0.7)
Blood and plasma donors 0 (0.0) 1 (0.3)
Unknown 74 (24.7) 69 (22.6)
CD4 cells/mm3 <200 134 (44.8) 103 (33.8) 0.019
200-500 141 (47.2) 176 (57.7)
>500 24 (8.0) 26 (8.5)
HAART 229 (76.6) 273 (89.5) 0.00002
Antiretroviral regimen c 2NRTIs + 1NNRTI 219 (95.6) 262 (96.0) 0.851
2NRTIs + 1PI 10 (4.4) 11 (4.0)
a Mann-Whithney test.
b Chi-square test.
c NRTIs, nucleoside reverse transcriptase inhibitors; NNRTI, non-nucleoside reverse transcriptase inhibitor; PI, protease inhibitor.
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Kunming, Yunnan Province to date. This province has been
heavily hit by HIV infection [2,3] but similar research has
rarely been performed before. As oral yeast colonization
can be affected by different factors, especially oral hygiene,
we only analyzed patients with HIV and healthy controls
from Kunming to eliminate potential influence of geo-
graphic region and oral hygiene habits of urban and rural
residents. The overall pattern of oral yeast colonization in
Chinese patients from Kunming was similar to those of
previously described in other populations [6,7,17], but also
Table 3 Antifungal susceptibility profile of 320 oral yeast isolates from HIV-infected patients from Kunming, China
Species (No.) Antifungal agent MIC range (μg/mL) No. of S strains (%) a No. of S-DD strains (%) b No. of R strains (%) c
C. albicans (263) Fluconazole 0.125-64 251 (95.0) 3 (1.1) 9 (3.4)
Itraconazole 0.031-16 232 (88.2) 13 (4.9) 18 (6.8)
Voriconazole 0.031-16 255 (97.0) - 8 (3.0)
Amphotericin B 0.125-1 263 (100.0) - 0 (0)
C. glabrata (29) Fluconazole 0.25-64 23 (79.3) 1 (3.4) 5 (17.2)
Itraconazole 0.031-16 7 (24.1) 7 (24.1) 15 (51.7)
Voriconazole 0.031-16 25 (86.2) - 4 (13.8)
Amphotericin B 0.25-1 29 (100.0) - 0 (0)
C. krusei (10) Fluconazole 8-64 3 (30.0) 5 (50.0) 2 (20.0)
Itraconazole 0.125-4 1 (10.0) 3 (30.0) 6 (60.0)
Voriconazole 0.063-2 8 (80.0) - 2 (20.0)
Amphotericin B 0.25-1 10 (100.0) - 0 (0)
C. tropicalis (2) Fluconazole 64 0 (0) 0 (0) 2 (100)
Itraconazole 16 0 (0) 0 (0) 2 (100)
Voriconazole 16 0 (0) - 2 (100)
Amphotericin B 0.5-1 2 (100.0) - 0 (0)
C. parapsilosis (12) Fluconazole 0.125-1 12 (100.0) 0 (0) 0 (0)
Itraconazole 0.031-2 6 (50.0) 4 (33.3) 2 (16.7)
Voriconazole 0.031 12 (100.0) - 0 (0)
Amphotericin B 0.25-1 12 (100.0) - 0 (0)
C. rugosa (1) Fluconazole 1 1 (100.0) 0 (0) 0 (0)
Itraconazole 0.031 1 (100.0) 0 (0) 0 (0)
Voriconazole 0.031 1 (100.0) - 0 (0)
Amphotericin B 0.5 1 (100.0) - 0 (0)
C. norvegensis (1) Fluconazole 1 1 (100.0) 0 (0) 0 (0)
Itraconazole 0.25 1 (100.0) 0 (0) 0 (0)
Voriconazole 0.063 1 (100.0) - 0 (0)
Amphotericin B 1 1 (100.0) - 0 (0)
Pichia ohmeri (1) Fluconazole 8 1 (100.0) 0 (0) 0 (0)
Itraconazole 2 0 (0) 0 (0) 1 (100)
Voriconazole 0.125 1 (100.0) - 0 (0)
Amphotericin B 0.5 1 (100.0) - 0 (0)
Saccharomyces cerevisiae (1) Fluconazole 16 0 (0) 1 (100.0) 0 (0)
Itraconazole 0.25 0 (0) 1 (100.0) 0 (0)
Voriconazole 0.125 1 (100.0) - 0 (0)
Amphotericin B 1 1 (100.0) - 0 (0)
a Susceptible (S) strains were defined by MIC ≤8 μg/mL for fluconazole, ≤0.125 μg/mL for itraconazole, <1 μg/mL for voriconazole and ≤ 1 μg/mL for
amphotericin B.
b Susceptible-dose dependent (S-DD) strains were defined by MICs between 16 μg/mL and 32 μg/mL for fluconazole and between 0.25 μg/mL and 0.5 μg/mL
for itraconazole.
c Resistant (R) strains were defined by MIC ≥64 μg/mL for fluconazole, ≥1 μg/mL for itraconazole and voriconazole, and >1 μg/mL for amphotericin B.
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presented some population- and/or region- unique features.
The reported oral yeast carriage rate of HIV-infected
patients varied in different populations across world, mainly
due to the different approaches for yeast sampling and geo-
graphic and/or ethnic differences [25]. The colonization
rate (49.5%) in Han Chinese patients infected with HIV
from Kunming was similar to that of Brazilian [11,19], but
lower than that of South Indian [9,26] and higher than that
of Han Chinese in Beijing, China [27]. Most of previous
studies showed a higher prevalence of asymptomatic oral
yeast carriage in HIV-infected patients than in healthy
group [6,7,17] and this pattern was also confirmed in the
current study.
Among the yeast species identified in Han Chinese
patients with HIV from Kunming, Candida albicans was
the predominant one (82.2%). This observation was con-
sistent with previous observations for Tanzanian patients
[10] and Brazilian patients [19]. A total of 57 (17.8%)
Table 4 Antifungal susceptibility profile of 179 oral yeast isolates from 851 healthy subjects from Kunming, China
Species (No.) Antifungal agent MIC range (μg/mL) No. of S strains (%) a No. of S-DD strains (%) b No. of R strains (%) c
C. albicans (131) Fluconazole 0.125-64 127 (96.9) 2 (1.5) 2 (1.5)
Itraconazole 0.031-16 121 (92.4) 2 (1.5) 8 (6.1)
Voriconazole 0.031-8 129 (98.5) - 2 (1.5)
Amphotericin B 0.125-1 131 (100.0) - 0 (0)
C. glabrata (17) Fluconazole 0.25-64 15 (88.2) 0 (0) 2 (11.8)
Itraconazole 0.031-16 6 (35.3) 0 (0) 11 (64.7)
Voriconazole 0.031-8 16 (94.1) 1 (5.9)
Amphotericin B 0.5-1 17 (100.0) - 0 (0)
C. krusei (3) Fluconazole 4-64 2 (66.7) 0 (0) 1 (33.3)
Itraconazole 1-2 0 (0) 0 (0) 3 (100)
Voriconazole 0.125-2 2 (66.7) - 1 (33.3)
Amphotericin B 0.5-1 3 (100.0) - 0 (0)
C. tropicalis (4) Fluconazole 0.25-4 4 (100.0) 0 (0) 0 (0)
Itraconazole 0.031-0.25 2 (50.0) 2 (50.0) 0 (0)
Voriconazole 0.031-0.063 4 (100.0) - 0 (0)
Amphotericin B 0.5-1 4 (100.0) - 0 (0)
C. parapsilosis (21) Fluconazole 0.125-2 21 (100.0) 0 (0) 0 (0)
Itraconazole 0.031-0.25 13 (61.9) 8 (38.1) 0 (0)
Voriconazole 0.031-0.25 21 (100.0) - 0 (0)
Amphotericin B 0.25-1 21 (100.0) - 0 (0)
C. lusitaniae (1) Fluconazole 0.25 1 (100.0) 0 (0) 0 (0)
Itraconazole 0.031 1 (100.0) 0 (0) 0 (0)
Voriconazole 0.031 1 (100.0) - 0 (0)
Amphotericin B 1 1 (100.0) - 0 (0)
C. guilliermondii (1) Fluconazole 4 1 (100.0) 0 (0) 0 (0)
Itraconazole 0.5 0 (0) 1 (100.0) 0 (0)
Voriconazole 0.063 1 (100.0) - 0 (0)
Amphotericin B 1 1 (100.0) - 0 (0)
Pichia ohmeri (1) Fluconazole 2 1 (100.0) 0 (0) 0 (0)
Itraconazole 2 0 (0) 0 (0) 1 (100)
Voriconazole 0.063 1 (100.0) - 0 (0)
Amphotericin B 1 1 (100.0) - 0 (0)
a Susceptible (S) strains were defined by MIC ≤8 μg/mL for fluconazole, ≤0.125 μg/mL for itraconazole, <1 μg/mL for voriconazole and ≤ 1 μg/mL for
amphotericin B.
b Susceptible-dose dependent (S-DD) strains were defined by MICs between 16 μg/mL and 32 μg/mL for fluconazole and between 0.25 μg/mL and 0.5 μg/mL
for itraconazole.
c Resistant (R) strains were defined by MIC ≥64 μg/mL for fluconazole, ≥1 μg/mL for itraconazole and voriconazole, and >1 μg/mL for amphotericin B.
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non-C. albicans yeast strains that belonged to eight spe-
cies were found in our HIV-infected patients, but the
frequency of non-C. albicans yeast strains in our colo-
nized samples was much lower than that of colonized
patients in Turkey (50.9%) [28] and in Brazil (50.0%) [8].
The exact reason for this discrepancy remains unknown.
In addition, our result showed that the presence of cer-
tain non-C. albicans yeast species was not related to the
status of HIV infection in Han Chinese from Kunming,
and a substantial proportion of healthy donors were also
colonized with non-C. albicans yeast species. This obser-
vation gave indirect support that colonization of non-C.
albicans yeast species was merely by chance. Previous
studies have shown a trend towards the increase of non-
C. albicans yeast species colonization in patients with
HIV [8], and this trend had been elegantly demonstrated
by a retrospective report in Chinese patients from
Taiwan, China, in which non-C. albicans yeast species
accounted for 9%, 14%, and 14.8% in years 1999, 2001,
and 2002, respectively [16]. We were unable to perform
such a test in this study as we only sampled these subjects
once. Repeated exposure to antifungal agents and recur-
rent infections might account for the high colonization of
the non-C. albicans species [14]. In contrast to the previ-
ous studies, we failed to find C. dubliniensis, which was
initially isolated from HIV-infected patients with oropha-
ryngeal candidosis [29] and HIV-negative individuals [7].
The absence of C. dubliniensis in our samples suggested
for a restricted distribution of this species.
Co-colonization of multiple yeast species in oral cavity
has been found in many studies [9,22,28]. In our study,
7% (21/299) of colonized HIV-infected patients and 1.7%
(3/176) colonized healthy individuals had multiple yeast
isolates. In particular, combination of C. albicans and C.
glabrata was the predominant type. This observation is
different from that of South Indian, in which colonization
of both C. albicans and C. krusei was the most common
and there was a colonization of three Candida species [9].
Among the three healthy individuals with colonization
of multiple yeast species, one with C. albicans and C. tro-
picalis and two with C. albicans and C. glabrata, it would
be interesting to have follow-up examinations for these
individuals. The exact reason for the presence of C. lusita-
niae and C. guilliermondii in healthy donors but not in
any HIV-infected patients remains elusive.
For prospective identification of yeasts, additional appli-
cation of updated methods, e.g. techniques which pro-
vide splitting up of Candida parapsilosis, C. metapsilosis,
C. orthopsilosis and other related species, as well as to
recognize potential new species will be employed in future
studies. This would be of interest because there is a species
specific difference in clinical relevance between Candida
species, e.g. between C. metapsilosis and C. orthopsilosis
[30]. Moreover, it would be rewarding to have a long-
term surveillance program for monitoring the dynamics
of the species in colonized HIV-infected patients and
healthy individuals.
Oral yeast colonization in Han Chinese patients infected
with HIV was associated with CD4 cell number and
HARRT
There was a debate over whether low CD4 cell count
was associated with asymptomatic oral yeast carriage. In
an early study, Fong et al. [6] found that the frequency
of C. albicans carriage, the concentration of yeasts iso-
lated and the development of thrush were all associated
to CD4 cell count in patients from Canada. Delgado
et al. [19] reported that Brazilian patients with CD4 cell
count <200 cells/mm3 had significantly higher incidence
of Candida in oral cavity. However, in another study
based on 45 patients with HIV (23 female and 22 male),
Back-Brito et al. [7] claimed that yeast carriage and Can-
dida load were not associated with CD4 cell count; this
negative observation might be caused by the relatively
small number of patients analyzed. In this study, we ana-
lyzed 604 Han Chinese with HIV from Kunming and we
thought our sample could help to solve this dispute. We
found that asymptomatic oral yeast carriage was asso-
ciated with a low CD4 cell count in our patients and
CD4 cell count less than 200 cells/mm3 could be used as
a predicted factor for yeast colonization (Table 2 and
Additional file 2).
HAART has been said to strikingly decrease the rate of
HIV-related opportunistic infections [16]. Absence of
HAART increased colonization of Candida spp. in HIV-
infected children from Brazil [17]. Antiretroviral protease
inhibitors containing HIV aspartyl protease inhibitors
could increase CD4 cell count [18] and inhibited the fun-
gal secretory aspartyl proteinases, thus leading to reduced
Candida infection during mucosal invasion [17]. In the
present study, we found that patients without HAART
had a higher incidence of Candida colonization, but oral
yeast colonization had no association with the antiretro-
viral regimens including treatment with protease inhibitor.
The exact reason underling these seemingly conflicting
observations remains unknown. More samples undergo-
ing protease inhibitor therapy should be recruited to an-
swer this question in future study.
Candida species in Han Chinese patients from Kunming
had higher susceptibility to amphotericin B than to azole
agents
Antifungal testing of oral yeast isolates are crucial for the
selection of antifungal agents and the prediction of clinical
response in patients with HIV/AIDS [20,26]. In this study,
we tested the antifungal activities of four widely used
drugs in Kunming on yeast isolates. We found that a rela-
tively low percentage of C. albicans was resistant to
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voriconazole (3.0%), fluconazole (3.4%) and itraconazole
(6.8%). The activity of voriconazole was better than the
other two azole agents. However, a high azole-resistance
rate was found for non-C. albicans yeast species, particu-
larly for C. glabrata, C. krusei and C. tropicalis. All species
were susceptible to polyene antifungal, amphotericin B,
with a narrow range of MICs (Tables 3 and 4). This result
clearly suggested that amphotericin B should be used with
first priority in controlling Candida infection in Han
Chinese patients from Kunming under certain circum-
stance. Although antifungal prophylaxis is not generally
used in asymptomatic HIV positive patients, the antifun-
gal susceptibility profile of oral yeast isolates obtained in
this study will offer useful information for us to select
proper drug to treat potential patients with OPC.
Conclusions
By analyzing oral yeast colonization in 604 Han Chinese
with HIV and 851 healthy donors from Kunming, Yunnan
Province, we showed that HIV-infected patients had a
higher Candida colonization rate than that of normal con-
trols, which posed a higher risk for future symptomatic
infection in HIV-infected patients. C. albicans was the
predominant species for colonization in our samples.
Asymptomatic oral yeast colonization was associated with
low CD4 cell count (<200 cells/mm3) and the absence of
HAART in HIV-infected patients. Different yeast isolates
from Han Chinese with HIV presented different suscep-
tibility to fluconazole, itraconazole, and voriconazole.
Amphotericin B had the best inhibiting effect for all
isolates. Our results provide first hand information on
monitoring oral yeasts colonization in HIV-infected
patients from Kunming, Yunnan, and will direct future
medical treatment for these patients when they develop
OPC. We will pursue further investigation to more ex-
tensively define the epidemiology and antifungal profiles
of the Candida species in the future study.
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